Brind.

Evolent Health Reports EBITDA Boost from Maturing Aetna and Highmark Relationships

1 report, 1 independent Updated Fri 21:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Evolent Health reported that maturing relationships with Aetna and Highmark are expected to boost EBITDA. A Truist analyst raised their rating, stating that US$150 million of 2027 EBITDA is now more achievable due to these relationships. The analyst also noted that Evolent Health's growth has accelerated, even as its adjusted profit margin has narrowed.

From finchannel.com

Why it matters

Some supportBrind's analysis of the reports

The maturation of these contracts is expected to improve Evolent Health's profitability outlook. The analyst noted that concerns regarding proposed health-policy changes have been applied too broadly to the company.

From finchannel.com

Who's involved

  • AetnaHas a maturing relationship with Evolent Health that is expected to boost EBITDA.
  • HighmarkHas a maturing relationship with Evolent Health that is expected to boost EBITDA.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped